Table of Content

1 Key Insights

2 Executive Summary of Spinal Cord Injury

3 SWOT Analysis for Spinal Cord Injury

4 Spinal Cord Injury Market Overview at a Glance
4.1 Market Share (%) Distribution of Spinal Cord Injury In 2017
4.2 Market Share (%) Distribution of Spinal Cord Injury In 2030

5 Disease Background and Overview
5.1 Introduction
5.2 Etiology and description of SCI
5.3 Classification of SCI and cord syndromes
5.4 Pathophysiology
5.4.1 SCI associated conditions
5.5 Complications
5.6 Assessment of SCI
5.7 Biomarkers

6 Epidemiology and Patient Population
6.1 Key Findings
6.2 Assumptions and Rationale: 7MM

7 Country-wise Epidemiology of Spinal Cord Injury (SCI)
7.1 The United States
7.1.1 Incident cases of SCI
7.1.2 Prevalent cases of SCI
7.1.2.1 Gender-wise Prevalence of SCI
7.1.2.2 Prevalence of SCI by Causes
7.1.2.3 Prevalence of SCI at Neurological Level
7.2 EU-5 Countries
7.3 Germany
7.3.1 Incident cases of SCI
7.3.2 Prevalent cases of SCI
7.3.2.1 Gender-wise Prevalence of SCI
7.3.2.2 Prevalence of SCI by Causes
7.3.2.3 Prevalence of SCI at Neurological Level
7.4 France
7.4.1 Incident cases of SCI
7.4.2 Prevalent cases of SCI
7.4.2.1 Gender-wise Prevalence of SCI
7.4.2.2 Prevalence of SCI by Causes
7.4.2.3 Prevalence of SCI at Neurological Level
7.5 Italy
7.5.1 Incident cases of SCI
7.5.2 Prevalent cases of SCI
7.5.2.1 Gender-wise Prevalence of SCI
7.5.2.2 Prevalence of SCI by Causes
7.5.2.3 Prevalence of SCI at Neurological Level
7.6 Spain
7.6.1 Incident cases of SCI
7.6.2 Prevalent cases of SCI
7.6.2.1 Gender-wise Prevalence of SCI
7.6.2.2 Prevalence of SCI by Causes
7.6.2.3 Prevalence of SCI at Neurological Level
7.7 The UK
7.7.1 Incident cases of SCI
7.7.2 Prevalent cases of SCI
7.7.2.1 Gender-wise Prevalence of SCI
7.7.2.2 Prevalence of SCI by Causes
7.7.2.3 Prevalence of SCI at Neurological Level
7.8 Japan
7.8.1 Incident cases of SCI
7.8.2 Prevalent cases of SCI
7.8.2.1 Gender-wise Prevalence of SCI
7.8.2.2 Prevalence of SCI by Causes
7.8.2.3 Prevalence of SCI at Neurological Level

8 Treatment and Management
Acute Spinal Cord Injury
Chronic Spinal Cord Injury
8.1 Other interventions
8.1.1 Management of penetrating spine trauma
8.2 Post-treatment complications and their management
8.3 Treatment Guidelines
NICE Guidelines
Consortium for Spinal Cord Medicine Guidelines

9 Case Study
Penetrating Spinal Cord Injury

10 Patient Journey

11 Unmet Needs

12 Emerging Therapies
12.1 MC001: StemCyte
12.1.1 Product Description
12.1.2 Other Developmental Activities
12.1.3 Clinical Development
12.1.3.1 Clinical trials information
12.1.4 Safety and Efficacy
12.2 AST-OPC1: Lineage Cell Therapeutics
12.2.1 Product Description
12.2.2 Other Developmental Activities
12.2.3 Clinical Development
12.2.3.1 Clinical trials information
12.2.4 Safety and Efficacy
12.3 KP-100IT: Kringle Pharma
12.3.1 Product Description
12.3.2 Other Developmental Activities
12.3.3 Clinical Development
12.3.3.1 Clinical trials information
12.3.4 Safety and Efficacy
12.4 Elezanumab: AbbVie
12.4.1 Product Description
12.4.2 Other Developmental Activities
12.4.3 Clinical Development
12.4.3.1 Clinical trials information
12.5 Stemirac: Nipro Corporation
12.5.1 Product Description
12.5.2 Other Developmental Activities
12.5.3 Clinical Development
12.5.4 Safety and Efficacy

13 Other Promising Candidates
13.1 AXER-204: ReNetX Bio, Inc.
13.1.1 Product Description
13.1.2 Other Development Activity
13.1.3 Clinical Development
13.1.3.1 Clinical trials information
13.2 NFX88: Neurofix
13.2.1 Product Description

14 Spinal Cord Injury: 7 Major Market Analysis
14.1 Key Findings
14.2 Market Size of Spinal Cord Injury (SCI) in 7MM

15 Market Outlook by Country
15.1 Assumption and Rationale
15.2 United States
15.2.1 Total Market size of Spinal Cord Injury
15.2.2 Spinal Cord Injury Market Size by Therapies
15.3 EU5 Countries
15.3.1 Germany
15.3.1.1 Total Market size of Spinal Cord Injury
15.3.1.2 Spinal Cord Injury Market Size by Therapies
15.3.2 France
15.3.2.1 Total Market size of Spinal Cord Injury
15.3.2.2 Spinal Cord Injury Market Size by Therapies
15.3.3 Italy
15.3.3.1 Total Market size of Spinal Cord Injury
15.3.3.2 Spinal Cord Injury Market Size by Therapies
15.3.4 Spain
15.3.4.1 Total Market size of Spinal Cord Injury
15.3.4.2 Spinal Cord Injury Market Size by Therapies
15.3.5 United Kingdom
15.3.5.1 Total Market size of Spinal Cord Injury
15.3.5.2 Spinal Cord Injury Market Size by Therapies
15.4 Japan
15.4.1 Total Market size of Spinal Cord Injury
15.4.2 Spinal Cord Injury Market Size by Therapies

16 Market Drivers

17 Market Barriers

18 Appendix
18.1 Report Methodology

19 DelveInsight Capabilities

20 Disclaimer

21 About DelveInsight



List of Figures


Figure 1: SWOT Analysis
Figure 2: Cascade of pathophysiological mechanisms
Figure 3: Overview of spinal cord injury pathophysiology
Figure 4: Incident cases of SCI in the United States (2017–2030)
Figure 5: Prevalent Cases of SCI in the United States (2017–2030)
Figure 6: Gender-wise Prevalence of SCI in the United States (2017–2030)
Figure 7: Prevalence of SCI by Causes in the United States (2017–2030)
Figure 8: Prevalence of SCI at Neurological Level in the United States (2017–2030)
Figure 9: Incident cases of SCI in Germany (2017–2030)
Figure 10: Prevalent Cases of SCI in Germany (2017–2030)
Figure 11: Gender-wise Prevalence of SCI in Germany (2017–2030)
Figure 12: Prevalence of SCI by Causes in Germany (2017–2030)
Figure 13: Prevalence of SCI at Neurological Level in Germany (2017–2030)
Figure 14: Incident cases of SCI in France (2017–2030)
Figure 15: Prevalent Cases of SCI in France (2017–2030)
Figure 16: Gender-wise Prevalence of SCI in France (2017–2030)
Figure 17: Prevalence of SCI by Causes in France (2017–2030)
Figure 18: Prevalence of SCI at Neurological Level in France (2017–2030)
Figure 19: Incident cases of SCI in Italy (2017–2030)
Figure 20: Prevalent Cases of SCI in Italy (2017–2030)
Figure 21: Gender-wise Prevalence of SCI in Italy (2017–2030)
Figure 22: Prevalence of SCI by Causes in Italy (2017–2030)
Figure 23: Prevalence of SCI at Neurological Level in Italy(2017–2030)
Figure 24: Incident cases of SCI in Spain (2017–2030)
Figure 25: Prevalent Cases of SCI in Spain(2017–2030)
Figure 26: Gender-wise Prevalence of SCI in Spain (2017–2030)
Figure 27: Prevalence of SCI by Causes in Spain (2017–2030)
Figure 28: Prevalence of SCI at Neurological Level in Spain (2017–2030)
Figure 29: Incident cases of SCI in the United Kingdom (2017–2030)
Figure 30: Prevalent Cases of SCI in the United Kingdom (2017–2030)
Figure 31: Gender-wise Prevalence of SCI in the United Kingdom (2017–2030)
Figure 32: Prevalence of SCI by Causes in the United Kingdom (2017–2030)
Figure 33: Prevalence of SCI at Neurological Level in the United Kingdom (2017–2030)
Figure 34: Incident cases of SCI in Japan (2017–2030)
Figure 35: Prevalent Cases of SCI in Japan (2017–2030)
Figure 36: Gender-wise Prevalence of SCI in Japan (2017–2030)
Figure 37: Prevalence of SCI by Causes in Japan (2017–2030)
Figure 38: Prevalence of SCI at Neurological Level in Japan (2017–2030)
Figure 39: Patient Journey for management of SCI
Figure 40: Unmet Needs
Figure 41: 7 Major Market Size of Spinal Cord Injury in USD Million (2017–2030)
Figure 42: Market Size of SPINAL CORD INJURY in the United States, USD Millions (2017–2030)
Figure 43: The US market size of Spinal Cord Injury by therapies in USD Million (2017–2030)
Figure 44: Market Size of Spinal Cord Injury in Germany, USD Millions (2017–2030)
Figure 45: Germany market size of Spinal Cord Injury by therapies in USD Million (2017–2030)
Figure 46: Market Size of Spinal Cord Injury in France, USD Millions (2017–2030)
Figure 47: France market size of Spinal Cord Injury by therapies in USD Million (2017–2030)
Figure 48: Market Size of Spinal Cord Injury in Italy, USD Millions (2017–2030)
Figure 49: Italy market size of Spinal Cord Injury by therapies in USD Million (2017–2030)
Figure 50: Market Size of Spinal Cord Injury in Spain, USD Millions (2017–2030)
Figure 51: Spain market size of Spinal Cord Injury by therapies in USD Million (2017–2030)
Figure 52: Market Size of Spinal Cord Injury in the UK, USD Millions (2017–2030)
Figure 53: The UK market size of Spinal Cord Injury by therapies in USD Million (2017–2030)
Figure 54: Market Size of Spinal Cord Injury in Japan, USD Millions (2017–2030)
Figure 55: Japan market size of Spinal Cord Injury by therapies in USD Million (2017–2030)
Figure 56: Market drivers for SCI
Figure 57:Market Barriers


List of Tables


Table 1: Summary of SCI Market, Epidemiology, and Key Events (2017–2030)
Table 2: The American Spinal Injury Association (ASIA) impairment scale
Table 3: Key-stages of the spinal cord response to closed trauma
Table 4: Incident Cases of SCI in the United States (2017–2030)
Table 5: Prevalent Cases of SCI in the United States (2017–2030)
Table 6: Gender-wise Prevalence of SCI in the United States (2017–2030)
Table 7: Prevalence of SCI by Causes in the United States (2017–2030)
Table 8: Prevalence of SCI at Neurological Level in the United States (2017–2030)
Table 9: Incident Cases of SCI in Germany (2017–2030)
Table 10: Prevalent Cases of SCI in Germany (2017–2030)
Table 11: Gender-wise Prevalence of SCI in Germany (2017–2030)
Table 12: Prevalence of SCI by Causes in Germany (2017–2030)
Table 13: Prevalence of SCI at Neurological Level in Germany (2017–2030)
Table 14: Incident Cases of SCI in France (2017–2030)
Table 15: Prevalent Cases of SCI in France (2017–2030)
Table 16: Gender-wise Prevalence of SCI in France (2017–2030)
Table 17: Prevalence of SCI by Causes in France (2017–2030)
Table 18: Prevalence of SCI at Neurological Level in France (2017–2030)
Table 19: Incident Cases of SCI in Italy (2017–2030)
Table 20: Prevalent Cases of SCI in Italy (2017–2030)
Table 21: Gender-wise Prevalence of SCI in Italy (2017–2030)
Table 22: Prevalence of SCI by Causes in Italy (2017–2030)
Table 23: Prevalence of SCI at Neurological Level in Italy (2017–2030)
Table 24: Incident Cases of SCI in the United States (2017–2030)
Table 25: Prevalent Cases of SCI in Spain (2017–2030)
Table 26: Gender-wise Prevalence of SCI in Spain (2017–2030)
Table 27: Prevalence of SCI by Causes in Spain (2017–2030)
Table 28: Prevalence of SCI at Neurological Level in Spain (2017–2030)
Table 29: Incident Cases of SCI in the United Kingdom (2017–2030)
Table 30: Prevalent Cases of SCI in the United Kingdom (2017–2030)
Table 31: Gender-wise Prevalence of SCI in the United Kingdom (2017–2030)
Table 32: Prevalence of SCI by Causes in the United Kingdom (2017–2030)
Table 33: Prevalence of SCI at Neurological Level in the United Kingdom (2017–2030)
Table 34: Incident Cases of SCI in Japan (2017–2030)
Table 35: Prevalent Cases of SCI in Japan (2017–2030)
Table 36: Gender-wise Prevalence of SCI in Japan (2017–2030)
Table 37: Prevalence of SCI by Causes in Japan (2017–2030)
Table 38: Prevalence of SCI at Neurological Level in Japan (2017–2030)
Table 39: MC001, Clinical Trial Description, 2020
Table 40: AST-OPC1, Clinical Trial Description, 2020
Table 41: KP-100IT, Clinical Trial Description, 2020
Table 42: Elezanumab, Clinical Trial Description, 2020
Table 43: AXER-204, Clinical Trial Description, 2020
Table 44: Seven Major Market Size of Spinal Cord Injury in USD Million (2017–2030)
Table 45: The US Market size of Spinal Cord Injury in USD Million (2017–2030)
Table 46: The US market size of Spinal Cord Injury by Therapies in USD Million (2017–2030)
Table 47: Germany Market size of Spinal Cord Injury in USD Million (2017–2030)
Table 48: Germany market size of Spinal Cord Injury by Therapies in USD Million (2017–2030)
Table 49: France Market size of Spinal Cord Injury in USD Million (2017–2030)
Table 50: France market size of Spinal Cord Injury by Therapies in USD Million (2017–2030)
Table 51: Italy Market size of Spinal Cord Injury in USD Million (2017–2030)
Table 52: Italy market size of Spinal Cord Injury by Therapies in USD Million (2017–2030)
Table 53: Spain Market size of Spinal Cord Injury in USD Million (2017–2030)
Table 54: Spain market size of Spinal Cord Injury by Therapies in USD Million (2017–2030)
Table 55: The Spinal Cord Injury Market size of Spinal Cord Injury in USD Million (2017–2030)
Table 56: UK market size of Spinal Cord Injury by Therapies in USD Million (2017–2030)
Table 57: Japan Market size of Spinal Cord Injury in USD Million (2017–2030)
Table 58:Japan market size of Spinal Cord Injury by Therapies in USD Million (2017–2030)